Background/Aims: Synthetic estrogens induce hypospadias, an anomaly of genital tubercle/urethral development. Activating transcription factor 3 (ATF3), which is estrogen-responsive in vitro, is upregulated in hypospadiac human tissue. We used a mouse model of steroid-dependent genital tubercle development to elucidate the ontogeny of ATF3 expression and the developmental response of ATF3 in vivo to estrogen exposure. Methods: We used quantitative RT-PCR to assess ontogenic expression of ATF3 and its response to estrogen treatment in utero. Immunohistochemistry was used to localize the protein. Results: Quantitative RT-PCR showed that ATF3 mRNA is upregulated in all estrogen-exposed fetal genital tubercles compared to controls (p = 0.024), including specifically in males exposed in utero (p = 0.049). Additionally, its expression increases significantly during the period of sexual differentiation in both sexes and significantly correlates with female development (p = 0.004), a phenomenon that appears to be attributable to higher levels at birth in females. The protein localizes in the nucleus, as expected. Conclusions: ATF3 is estrogen-responsive in vivo. The response of ATF3 to estrogenic stimulation in utero at an earlier stage may contribute to urethral abnormalities observed in estrogen-exposed male fetuses, although it is likely not the only gene involved, which supports the general understanding that hypospadias is subject to multifactorial influences. ATF3 may therefore be an appropriate gene for further investigations in an endocrine context.

Keywords:
Activating transcription factor 3, Transcription factor, Estrogen, Hypospadias, Endocrine disrupters, Genitourinary abnormalities, Sex differentiation
1.
Baskin LS: Hypospadias. Adv Exp Med Biol 2004;545:3–22.
2.
Paulozzi LJ, Lary JM: Laterality patterns in infants with external birth defects. Teratology 1999;60:265–271.
3.
Baskin LS, Himes K, Colborn T: Hypospadias and endocrine disruption: is there a connection? Environ Health Perspect 2001;109:1175–1183.
4.
Baskin LS, Erol A, Jegatheesan P, Li Y, Liu W, Cunha GR: Urethral seam formation and hypospadias. Cell Tissue Res 2001;305:379–387.
5.
Baskin LS, Liu W, Bastacky J, Yucel S: Anatomical studies of the mouse genital tubercle. Adv Exp Med Biol 2004;545:103–121.
6.
Steinhardt GF: Endocrine disruption and hypospadias. Adv Exp Med Biol 2004;545:203–215.
7.
Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S: Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 2002;29:175–192.
8.
Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER: Integration of the non-genomic and genomic actions of estrogen membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 2002;277:50768–50775.
9.
Liu B, Wang Z, Lin G, Agras K, Ebbers M, Willingham E, Baskin LS: Activating transcription factor 3 is upregulated in patients with hypospadias. Pediatr Res 2005;58:1280–1283.
10.
Kim KS, Torres CR Jr, Yucel S, Raimondo K, Cunha GR, Baskin LS: Induction of hypospadias in a murine model by maternal exposure to synthetic estrogens. Environ Res 2004;94:267–275.
11.
Fan F, Jin S, Amundson SA, Tong T, Fan W, Zhao H, Zhu X, Mazzacurati L, Li X, Petrik KL, Fornace AJ Jr, Rajasekaran B, Zhan Q: ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 2002;21:7488–7496.
12.
Baskin LS: Hypospadias and urethral development. J Urol 2000;163:951–956.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.